Clinical factors associated with hyponatremia correction during treatment with oral urea
Nephrology Dialysis Transplantation · 2025
DOI: 10.1093/ndt/gfae164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Anissa Pelouto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Hyponatremia, Urea. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss National Science Foundation.
Abstract (Originalsprache)
Background
Oral urea is being used more commonly to treat hyponatremia, but factors contributing to the correction rate are unknown. We hypothesized that clinically relevant factors can be identified to help guide hyponatremia correction with oral urea.
Methods
This was a retrospective study in two university hospitals including hospitalized patients with hyponatremia (plasma sodium <135 mmol/L) treated with oral urea. Linear mixed-effects models were used to identify factors associated with hyponatremia correction. Rates of overcorrection, osmotic demyelination and treatment discontinuation were also assessed.
Results
We included 161 urea treatment episodes in 140 patients (median age 69 years, 46% females, 93% syndrome of inappropriate antidiuresis). Oral urea succeeded fluid restriction in 117 treatment episodes (73%), was combined with fluid restriction in 104 treatment episodes (65%) and was given as the only treatment in 27 treatment episodes (17%). A median dose of 30 g/day of urea for 4 days (interquartile range 2–7 days) increased plasma sodium from 127 to 134 mmol/L and normalized hyponatremia in 47% of treatment episodes. Older age (β 0.09, 95% CI 0.02–0.16), lower baseline plasma sodium (β –0.65, 95% CI –0.78 to –0.62) and higher cumulative urea dose (β 0.03, 95% CI –0.02 to –0.03) were independently associated with a greater rise in plasma sodium. Concurrent fluid restriction was associated with a greater rise in plasma sodium only during the first 48 h of treatment (β 1.81, 95% CI 0.40–3.08). Overcorrection occurred in 5 cases (3%), no cases of osmotic demyelination were identified and oral urea was discontinued in 11 cases (11%) due to side effects.
Conclusion
During treatment with oral urea, older age, higher cumulative dose, lower baseline plasma sodium and initial fluid restriction are associated with a greater correction rate of hyponatremia. These factors may guide clinicians to achieve a gradual correction of hyponatremia with oral urea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
- Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
- Department of Clinical Research, University of Basel, Basel, Switzerland.
ORCID-Profile: Anissa Pelouto, Sophie Monnerat, Mirjam Christ-Crain, Ewout J Hoorn
Förderung
- Swiss National Science Foundation
Zitieren
APA
Pelouto, A., Monnerat, S., Refardt, J., Zandbergen, A. A. M., Christ-Crain, M., & Hoorn, E. J. (2025). Clinical factors associated with hyponatremia correction during treatment with oral urea. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae164
Vancouver
Pelouto A, Monnerat S, Refardt J, Zandbergen AAM, Christ-Crain M, Hoorn EJ. Clinical factors associated with hyponatremia correction during treatment with oral urea. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfae164
BibTeX
@article{Pelouto2025,
author = {Pelouto, Anissa and Monnerat, Sophie and Refardt, Julie and Zandbergen, Adrienne A M and Christ-Crain, Mirjam and Hoorn, Ewout J},
title = {Clinical factors associated with hyponatremia correction during treatment with oral urea},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
doi = {10.1093/ndt/gfae164}
}
EUVIMED